combination vaccine News
-
Vaccine trial to investigate a booster for teenagers to protect against COVID-19
Researchers running the University of Oxford-led Com-COV programme have launched a further national study assessing different options for a (third dose) booster vaccination for young people aged 12 to 15. Backed through funding from the Vaccines Taskforce and National Institute for Health Research (NIHR), the Com-COV 3 trial will seek to recruit 270 volunteers across the UK. In Wales, up to 40 ...
By MediWales
-
China risks between 1.3 and 2.1 million deaths if it ends its zero-COVID strategy
Analysis by Airfinity shows between 1.3 and 2.1 million lives could be at risk if China lifts its zero-COVID policy given low vaccination and booster rates as well as a lack of hybrid immunity. Airfinity’s risk analysis uses cumulative peak cases and deaths from Hong Kong's BA.1 wave as a proxy for mainland China. Hong Kong took a zero-COVID approach for the first two years of the ...
-
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. ...
By Novavax
-
ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs
ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ECI® (ELIAS Cancer Immunotherapy) resulted in a median survival time ...
-
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of a new class of immunotherapeutic vaccines, today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ ...
By Vaxxinit
-
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical ...
-
Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of ...
-
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for BW-1010, the company’s next-generation anthrax vaccine candidate. The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and ...
-
Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimicsTM vaccine, EO2463, in non-Hodgkin lymphoma
EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine • EO2463 combines four microbiome-peptides of B lymphocytes-specific lineage markers designed to induce the full depletion of malignant B lymphocytes ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut ...
By Enterome
-
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary ...
-
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19 Oxford, UK, September 8: SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first ...
-
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. ATCC is a non-profit ...
-
Animal Vaccination: Our Best Defense Against the Next Pandemic
As cases of COVID-19 continue to rise, experts are raising alerts regarding the likelihood of the next pandemic, likely originating from a family of zoonotic influenza strains well-positioned for the jump from animals to humans. Similar to the SARS-CoV-2 virus (which causes COVID-19), many type A influenza viruses thrive in animal hosts as well as in humans. Examples of type A influenza include ...
-
POP Biotechnologies’ SNAP Vaccine Platform Enters Large Scale Clinical Trials for COVID-19
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces the commencement of two Phase 3 clinical studies of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO’s ...
-
Noble Awards $25,000 in Research Services to Synam Vaccine
Noble Awards $25,000 in Research Services to SynAm Vaccine Contributes Drug Development Services through InvestMaryland Business Competition Noble Life Sciences, Inc. (Gaithersburg, MD) awarded $25,000 of its drug development contract research services to SynAm Vaccine (Rockville, MD) as part of the InvestMaryland Challenge business competition. Organized by the state of Maryland, the ...
-
BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the ...
-
Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a partnership to develop S-2P-NE-01, a nasal vaccine for ...
-
Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil
Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that it has signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná (IBMP) in Brazil. IBMP is a ...
-
Emergex Announces GMP Production of its CD8+ T cell Universal Influenza Vaccine
Emergex will manufacture the candidate universal influenza vaccine to cGMP standards for use in Phase I human trials Emergex’s universal influenza vaccine is a radically different approach to inducing influenza immunity by employing the use of a combination of: Highly conserved Class I peptides from non-structural proteins (NSP) representative of pandemic influenza A strains which ...
-
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
Emergex’s CD8+ T cell Adaptive Vaccine platform will now be used to generate a tularemia vaccine candidate that provides a cytotoxic (killing of infected cells) CD8+ T cell response and offers a means for rapid development suitable for deployment as a medical countermeasure. Emergex’s ongoing Phase I clinical trials on vaccine candidates for Dengue Fever and COVID-19 are evaluating ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you